Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age 50 years or greater * Best corrected visual acuity letter score = 65 or greater (approximate Snellen equivalent of 20/50 or better in the candidate study eye) * Neovascular AMD in the fellow eye and no CNV in the candidate study eye (absence of CNV confirmed by FA which will be graded in a masked fashion by the AMD DOC Study Reading Center) * Candidate study eye must have evidence of at least one large druse (≥ 125µm) and focal hyperpigmentation within 3600μm of the fovea and visible on color fundus photography, red-free photograph, or fluorescein angiography * Participant must have media clear enough in the candidate study eye to permit fundus photography, fluorescein angiography, and optical coherence tomography and absence of any fluorescein allergies * Results of the baseline PHP and supervised Amsler grid will not affect eligibility of the participant. Subjects can be eligible for further follow-up even if they have positive PHP and Amsler grid * Eligible participants who have a positive PHP or supervised Amsler grid for that eye at the initial screening visit should have a second PHP or supervised Amsler grid screening visit within 2 weeks in order to repeat the PHP or Amsler test or the participant may repeat the PHP or Amsler grid that day before pupillary dilation. Participants with a 2nd positive PHP or supervised Amsler grid are still eligible for further follow-up * All tests (supervised Amsler grid, PHP, OCT, FA) must be performed within 2 weeks of each other * Participants with non-foveal geographic atrophy in the candidate study eye are still eligible for enrollment in the study Exclusion Criteria: * Known allergy to fluorescein angiography or allergic reaction during screening * Advanced AMD with CNV in both eyes confirmed on FA graded by the AMD DOC Study Reading Center * Foveal geographic atrophy in the study eye * Positive OCT test for the candidate study eye, as read by the AMD DOC Study Reading Center, for subretinal fluid, intraretinal edema, or retinal thickening that falls within the top 1% of the normative data base for the Stratus OCT * Significant media opacity that precludes reasonable quality retinal imaging including color fundus photographs, fluorescein angiography, or OCT in the candidate study eye to assess the presence of CNV * Evidence of macular disease (e.g., pattern dystrophy, diabetic macular edema, vitreomacular traction) other than AMD in the study eye * Previous surgical or laser treatment to the macula of the study eye * Diabetic retinopathy